Gilead Sciences, Inc.
NASDAQ:GILDDrug Manufacturers - General
-$2.69 today
- Market cap
- $209.59B
- Beta
- 0.33
- P/E (TTM)
- 16.5
- EPS (TTM)
- $7.42
- Dividend yield
- 2.62%
Volume 4.82M
Average 6.78M
GILD Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Gilead Sciences, Inc.NASDAQ: GILD
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization grows in line with its trailing trend
Q2 FY2026 depreciation & amortization of $698M rose 1.0% year over year, ahead of the -0.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.3% from the prior quarter. Over 3 fiscal years it compounded at +9.5% a year.
Context
- Depreciation & amortization amounted to 9.4% of revenue in FY2025, down 0.2 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +1.0% holds above the trailing-twelve-month pace of -0.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 2.76B USD
- Year-over-year change
- -0.3%
- 4-year CAGR
- +7.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.76B | -0.3% |
| FY2024 | 2024-12-31 | 2.77B | +2.7% |
| FY2023 | 2023-12-31 | 2.69B | +28.1% |
| FY2022 | 2022-12-31 | 2.1B | +2.6% |
| FY2021 | 2021-12-31 | 2.05B | — |
Depreciation & Amortization vs competitors
How GILD compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -0.4% is the 6th highest of 10, against a peer median of +9.5%.
- Depreciation & amortization amounts to 9.1% of revenue for GILD, versus a peer median of 10.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $8.09B USD | +9.5% | +2.5% | 8.1% | |
| LTM Jun 2026 | $7.87B USD | -4.8% | -1.3% | 12.2% | |
| LTM Jun 2026 | $6.72B USD | +45.9% | +14.3% | 10.1% | |
| LTM Jun 2026 | $6.58B USD | -3.0% | +9.2% | 10.3% | |
| LTM Sep 2026 | $6.41B USD | +29.8% | +3.0% | 10.3% | |
| LTM Jun 2026 | €5.88B EUR | +22.9% | +22.2% | 12.0% | |
| LTM Jun 2026 | $5.34B USD | -11.0% | -7.2% | 9.6% | |
| LTM Jun 2026 | $2.76B USD | -0.4% | +9.5% | 9.1% | |
| LTM Jun 2026 | £2.21B GBP | -34.0% | +2.5% | 6.7% | |
| LTM Jun 2026 | $2.1B USD | +10.9% | +9.5% | 2.6% | |
| Peer median (excluding GILD) | — | +9.5% | +3.0% | 10.1% | |
Competitors are the stored peer set for GILD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 6.2B | 4.59B | 5.67B | 480M | 8.51B |
| Depreciation & Amortization | 2.05B | 2.1B | 2.69B | 2.77B | 2.76B |
| Deferred Income Tax | (116M) | (1.55B) | (962M) | (1.84B) | 160M |
| Stock-Based Compensation | 635M | 644M | 766M | 835M | 894M |
| Change in Working Capital | 489M | (1.76B) | (2.3B) | (880M) | (3.95B) |
| Accounts Receivables | 313M | (406M) | 157M | 139M | (367M) |
| Inventory | 11M | (310M) | (842M) | (426M) | (1.04B) |
| Accounts Payables | (118M) | 226M | (347M) | 290M | (132M) |
| Other Working Capital | 283M | (1.27B) | (1.27B) | (883M) | (2.41B) |
| Other Non-Cash Items | 2.13B | 5.05B | 2.15B | 9.47B | 1.64B |
| Operating Cash Flow | 11.38B | 9.07B | 8.01B | 10.83B | 10.02B |
| Capital Expenditures | (579M) | (728M) | (585M) | (523M) | (563M) |
| Acquisitions (Net) | (1.58B) | (1.8B) | (1.15B) | (4.84B) | (1.07B) |
| Purchases of Investments | (3.9B) | (1.94B) | (2.37B) | (736M) | (4.07B) |
| Sales of Investments | 2.91B | 2B | 1.84B | 2.59B | 909M |
| Other Investing Activities | 19M | (1M) | 0 | 58M | 3M |
| Investing Cash Flow | (3.13B) | (2.47B) | (2.27B) | (3.45B) | (4.79B) |
| Debt Repayment | (4.75B) | (1.5B) | (270M) | 1.49B | (1.79B) |
| Common Stock Issued | 169M | 309M | 232M | 422M | 408M |
| Common Stock Repurchased | (546M) | (1.4B) | (1B) | (1.15B) | (1.92B) |
| Dividends Paid | (3.61B) | (3.71B) | (3.81B) | (3.92B) | (4B) |
| Other Financing Activities | (145M) | (173M) | (278M) | (281M) | (440M) |
| Financing Cash Flow | (8.88B) | (6.47B) | (5.13B) | (3.43B) | (7.75B) |
| Effect of Forex Changes | (35M) | (63M) | 57M | (40M) | 92M |
| Net Change in Cash | (659M) | 74M | 673M | 3.91B | (2.43B) |
| Free Cash Flow | 10.81B | 8.34B | 7.42B | 10.31B | 9.46B |
Gilead Sciences, Inc.
NASDAQ:GILD
Intrinsic Alpha fair value
Locked
Current Price
$168.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.